Essential Data on INI DRMs
Last updated on 2016-6-20
Prevalence of INI DRMs in ARV-naive and -treated patients and their contributions to reduced INI susceptibility
| DRM | HIVDB Score | SDRM | Prevalence (%) | Phenotypic Fold Resistance | ||
|---|---|---|---|---|---|---|
| ARV-Naive (n=10059) | ARV-Treated (n=1038) | RAL (n=302) | EVG (n=233) | |||
| N155H | 15 | 17 | ||||
| Q148H | 46 | 27 | ||||
| Q148R | 33 | 37 | ||||
| Y143R | 26 | 3 | ||||
| E92Q | 7 | 15 | ||||
| Y143C | 8 | 1.7 | ||||
| S147G | 1.0 | 5 | ||||
| Y143H | 3 | 1.1 | ||||
| T66I | 1.3 | 8 | ||||
| Q148K | 21 | >50 | ||||
| Y143S | 9 | 2 | ||||
| T66A | 1.1 | 6 | ||||
| Y143G | 12 | 3 | ||||
| F121Y | 8 | 34 | ||||
| Y143K | NA | NA | ||||
| T66K | 13 | 47 | ||||
| Y143A | 17 | 4 | ||||
| E92V | NA | NA | ||||
| P145S | NA | NA | ||||
| Q146P | NA | 12 | ||||
| V151L | NA | NA | ||||
| G140S | 3 | 7 | ||||
| G140A | 3 | 6 | ||||
| G140C | NA | NA | ||||
| R263K | 1.6 | 5 | ||||
| E92G | NA | NA | ||||
| V151A | NA | NA | ||||
| G118R | 4 | 3 | ||||
| N155T | NA | NA | ||||
| N155S | NA | NA | ||||
| E138K | 1.8 | 1.1 | ||||
| S230R | NA | NA | ||||
| E138A | 1.3 | 2 | ||||
| E138T | NA | NA | ||||
| H51Y | 1.2 | 3 | ||||
| Q148N | NA | NA | ||||
| S153F | 1.4 | 1.9 | ||||
| S153Y | 1.5 | 5 | ||||
| T97A | 4 | 4 | ||||
| E157Q | NA | NA | ||||
| G163R | 1.2 | 0.9 | ||||
| G163K | NA | NA | ||||
| Q95K | NA | NA | ||||
- Footnotes:
- HIVDB Score: The highest score for RAL (raltegravir) and EVG (elvitegravir).
- SDRM (Surveillance Drug Resistance Mutation): Nonpolymorphic DRMs that have been used for TDR surveillance (Bennett DE et al. PLoSOne 2009).
- Without Major DRMs: Primary DRMs are more likely to occur without additional DRMs. However, many co-occurring DRMs have primary roles in conferring resistance to different ARVs.
- Phenotypic Fold Resistance: The contribution of each DRM to reduced INI susceptibility (fold increase in the INI concentration required to inhibit a fixed virus inoculum by 50%) determined using published regression analyses. All results are based on susceptibility tests performed using the PhenoSense assay (Monogram, South San Francisco) or HeLa-CD4 reporter gene assay. The complete dataset used for the regression analyses is downloadable (HIVDB Genotype-Phenotype Dataset, http://hivdb.stanford.edu/cgi-bin/GenoPhenoDS.cgi. Red: Large contribution to reduced in vitro susceptibility. Pink: Statistically significant modest contribution to reduced in vitro susceptibility. Negative values indicate contribution to increased in vitro susceptibility.